Nuklearmedizin. Nuclear medicine最新文献

{"title":"Diagnostic value of presurgical 68Ga-PSMA-11 PET/CT in prostate cancer patients with different ISUP grade groups.","authors":"Berna Okudan, Merve Atalay, Zeynep Ruken Hakkoymaz, Bedri Seven, Berrak Gümüşkaya Öcal","doi":"10.1055/a-2665-8087","DOIUrl":"10.1055/a-2665-8087","url":null,"abstract":"<p><p>In our study, we aimed to investigate the correlation of preoperative ⁶⁸Ga-PSMA PET/CT imaging with pathology findings obtained from radical prostatectomy in patients diagnosed with adenocarcinoma by prostate biopsy.A total of 76 consecutive patients who were diagnosed prostate adenocarcinoma as a result of biopsy between 2019-2021 and who underwent ⁶⁸Ga-PSMA PET/CT imaging were retrospectively analyzed. The localization of the pathologically evaluated activity involvement areas, the largest diameter and SUVmax values were recorded. Sections of prostatectomy materials belonging to all cases were removed from the archive and re-evaluated by an experienced pathologist, and tumor areas were marked. As the gold standard, slices sampled in accordance with classical prostatectomy macroscopy rules were arranged from proximal to distal, the lesions were mapped, dominant nodule diameter and localization, lymph node (LN) metastases and seminal vesicle invasion (SVI) were recorded.Among 61 patients who underwent pelvic LN dissection, PET/CT was able to detect 16 of 18 patients with LN metastases. In the statistical analysis, a high degree of agreement was found between the histopathological and PET/CT results (p<0.05). Furthermore, a high degree of agreement was also observed between histopathological and PET/CT findings for detection of SVI (Kappa=0.808, p<0.05 for the right side and Kappa=0.774, p<0.05 for the left side).The findings of this study indicate that ⁶⁸Ga-PSMA PET/CT can be used to determine the localization and extent of prostate cancer. ⁶⁸Ga-PSMA PET/CT before radical prostatectomy can help identify target lesions and aid in decision-making regarding therapy.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"294-300"},"PeriodicalIF":1.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Performance of 99 mTc-Sestamibi SPECT/CT and 18F-Choline PET/CT in Locating Hyperfunctioning Parathyroid Glands in Patients with Primary Hyperparathyroidism.","authors":"Ante Mandic, Ivana Kraljevic, Tanja Skoric Polovina, Karin Zibar Tomsic, Tina Dusek, Annemarie Balasko, Mirsala Solak, Darko Kastelan","doi":"10.1055/a-2694-8426","DOIUrl":"https://doi.org/10.1055/a-2694-8426","url":null,"abstract":"<p><p>This study aimed to assess the diagnostic performance of ^99mTc-sestamibi SPECT/CT and ¹⁸F-choline PET/CT in detecting hyperfunctioning parathyroid glands in patients undergoing surgery for primary hyperparathyroidism (PHPT).A retrospective analysis was conducted on patients who underwent PHPT-related surgery between April 2019 and May 2022. The study focused on patients undergoing either ^99mTc-sestamibi SPECT/CT (81 patients) or ¹⁸F-choline PET/CT (33 patients) scans before surgery to pinpoint hyperfunctioning parathyroid gland(s). In the majority of patients, ¹⁸F-choline PET/CT was performed after negative or inconclusive findings on ^99mTc-sestamibi SPECT/CT. Pathohistological reports were utilized as the reference standard for evaluating the accuracy of the imaging findings.The study encompassed 83 patients (70 females, 84.3 %) with an average age of 57.2 years (24-80 years). The pathohistological analysis identified a total of 98 glands. In a per-lesion analysis, the detection rate of ^99mTc-sestamibi SPECT/CT was 57 % (95 % CI 45.3-68.1), while the detection rate of ¹⁸F-choline PET/CT was 90.3 % (95 % CI 74.3-98.0).The results of our study showed the significant usefulness of ¹⁸F-choline PET/CT in patients with negative or inconclusive results of ^99mTc-sestamibi SPECT/CT in accurately locating hyperfunctioning parathyroid glands in PHPT patients.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":"64 5","pages":"308-312"},"PeriodicalIF":1.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Digitalization of Nuclear Medicine in Germany - Status Quo 2024.","authors":"Thomas Wendler, Julian Manuel Michael Rogasch, Moritz B Bastian, Wolfgang Burchert, Dirk Hellwig, Lena Kaiser, Philipp Lohmann, Florian Rosar, Benedikt Schemmer, Johannes Tran-Gia, Isabelle Miederer","doi":"10.1055/a-2604-5823","DOIUrl":"10.1055/a-2604-5823","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"318"},"PeriodicalIF":1.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12473065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of 68Ga-NODAGA-Exendin-4 PET/CT Guided Surgical Management of Insulinomas in MEN1: A Preliminary Study.","authors":"Ketki Sunil Ambulkar, Ravikumar Shah, Anurag Lila, Anima Sharma, Rohit Barnabas, Manjiri Karlekar, Saba Samad Memon, Vijaya Sarathi, Sameer Rege, Priyanka Verma, Gaurav Malhotra, Vikram Lele, Tushar Bandgar","doi":"10.1055/a-2694-8248","DOIUrl":"https://doi.org/10.1055/a-2694-8248","url":null,"abstract":"<p><p>The data on the use of ⁶⁸Ga-NODAGA-exendin-4 PET/CT in localizing multiple endocrine neoplasia type 1 (MEN1)-related insulinomas is evolving; however, surgical outcomes data are not available. We describe our cohort of patients with MEN1-related endogenous hyperinsulinemic hypoglycemia (EHH), where ⁶⁸Ga-NODAGA-exendin-4 PET/CT was used to guide conservative surgery. A retrospective record review of MEN1-related EHH cases managed between 2000 and 2024 was performed for clinical features, imaging, and management. Outcomes were assessed for patients whose surgical extent was determined by ⁶⁸Ga-NODAGA-exendin-4 PET/CT versus conventional imaging (CECT and ⁶⁸Ga-DOTATATE PET/CT). Five patients with a median age of 17 (15.5-18.5 years) with EHH underwent laparoscopic, single lesion enucleation based on ⁶⁸Ga-NODAGA-exendin-4 PET/CT. On preoperative imaging, CT identified culprit lesion in four, while ⁶⁸Ga-DOTATATE PET/CT localized in one, and had one false positive uptake in non-functioning NET. The median duration of hospital stay was 6 (5.5-9) days. Over a median follow-up of 48 (3.5-84.5) months, none had EHH recurrence or exocrine/endocrine pancreatic insufficiency. On follow-up, one patient had an uneventful pregnancy and delivery. In the remaining 15, who underwent surgery based on conventional imaging, 12 (80 %) required extensive surgery beyond enucleation, of which two needed intraoperative ultrasound localization. This group had a postoperative hospital stay of 11 (8-23) days, one recurrence after 84 months, and pancreatic insufficiency in 5 (33 %). Our center observation suggests that GLP1R-based PET/CT-guided conservative insulinoma surgery in MEN1 patients is effective and safe and needs further validation.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":"64 5","pages":"301-307"},"PeriodicalIF":1.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic challenge in parathyroid imaging: incidental schwannoma mimicking primary hyperparathyroidism on 18F-fluorocholine PET/CT.","authors":"Vlatka Jozanovic, Dragana Lukic, Matija Brataljenovic, Drazen Huic","doi":"10.1055/a-2655-5291","DOIUrl":"10.1055/a-2655-5291","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"313-315"},"PeriodicalIF":1.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First clinical application of silicon-based [¹⁸F]siPSMA-14 in prostate cancer patients: A proof-of-concept study.","authors":"Jonathan Miksch, Elham Yousefzadeh-Nowshahr, Deni Hardiansyah, Gerhard Glatting, Christoph Solbach, Christian Bolenz, Friedemann Zengerling, Thomas Wiegel, Meinrad Beer, Vikas Prasad, Hans-Jürgen Wester, Ambros J Beer, Wolfgang Thaiss","doi":"10.1055/a-2652-3273","DOIUrl":"10.1055/a-2652-3273","url":null,"abstract":"<p><p>Silicon-based ligands are of interest in increasingly used Prostate-specific membrane antigen (PSMA) tracers for prostate cancer (PCa) staging due to their simple and scalable production. Here, we present first data on dosimetry and biodistribution of the novel PSMA-specific tracer [¹⁸F]siPSMA-14.Seven PCa patients referred for PSMA-PET/CT imaging were imaged at 60 and 120 min p.i. (T1 and T3), without forced diuresis, to assess organ absorbed (AD) and effective doses (ED). We matched seven of subsequent 134 patients imaged at 90 min. p. i. (T2) to the initial seven patients according to disease and patient characteristics. SUVs of organs and PCa lesions as well as target-to-non-target ratios (TnTR) were analyzed. Statistical analysis was done using paired t-tests and Mann-Whitney U tests.[¹⁸F]siPSMA-14 dosimetry showed an ED of 1.95E-02±0.25E-02 mSv/MBq with the highest AD in kidneys (1.40E-01±0.41E-01 mGy/MBq). Tracer uptake in lesions (SUVmax±SD) was intense in all patients and increased significantly over time (local lesions (intraprostatic lesions or local recurrences) T1: 10.6±4.5; T3: 14.0±5.9 (p=0.01); metastatic lesions: T1: 17.7±8.9; T3: 20.6±9.4 (p=0.01). PCa uptake at T2 was similar, without significant difference in interindividual comparison in local (T1 to T2: p=0.39; T2 to T3: p=1.0) and metastatic lesions (T1 to T2: p=0.79; T2 to T3: p=0.43).[¹⁸F]siPSMA-14 showed moderate effective doses comparable to other 18F- and 68Ga-labeled PCa tracers even without forced diuresis. Uptake in PCa lesions was high and in line with data for other PSMA specific tracers. This suggests that PET imaging with[¹⁸F]siPSMA-14 is safe and effective even without forced diuresis with the advantage of a simple and scalable production.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"285-293"},"PeriodicalIF":1.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atypical local laryngeal cancer recurrence mimicking thyroid uptake on 18F-FDG PET/CT.","authors":"Forough Kalantari, Gundula Rendl, Stefan Hecht, Christian Pirich, Mohsen Beheshti","doi":"10.1055/a-2694-8081","DOIUrl":"https://doi.org/10.1055/a-2694-8081","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":"64 5","pages":"316-317"},"PeriodicalIF":1.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145180760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Central Conducting Lymphatic Abnormalities in Noonan Syndrome Identified Using SPECT/CT Lymphoscintigraphy.","authors":"Tomonori Chikasue, Seiji Kurata, Shiori Edamitsu, Masamichi Koganemaru, Akiko Sumi, Kiminori Fujimoto, Shuichi Tanoue","doi":"10.1055/a-2695-8007","DOIUrl":"https://doi.org/10.1055/a-2695-8007","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[99mTc]Tc-PSMA SPECT/CT is a promising tool in the staging of renal cell carcinoma.","authors":"Marcel Baehr, Isabell Dietrich, Knut Liepe","doi":"10.1055/a-2578-7222","DOIUrl":"10.1055/a-2578-7222","url":null,"abstract":"","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"274-276"},"PeriodicalIF":1.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144046681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psycho-Oncological Screening Identifies High-Risk Subgroups Among Neuroendocrine Tumor Patients Undergoing PRRT with [177Lu]Lu-DOTATATE: Implications for Survival.","authors":"Barbara Kreppel, Hannah M Jochims, Milka Marinova, Jim Küppers, Ingo G H Schmidt-Wolf, Georg Feldmann, Maria Angeles Gonzalez-Carmona, Markus Essler","doi":"10.1055/a-2641-7759","DOIUrl":"10.1055/a-2641-7759","url":null,"abstract":"<p><p>Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies characterized by variable clinical presentations and significant psychological burdens. Peptide receptor radionuclide therapy (PRRT) with [¹⁷⁷Lu]Lu-DOTATATE is a cornerstone in managing somatostatin receptor-positive NETs. This study investigates the role of psycho-oncological screening using the Hornheider Screening Instrument (HSI) in identifying psychosocial distress and its impact on overall survival (OS) and progression-free survival (PFS) in NET patients undergoing PRRT.A cohort of 100 NET patients with progressive disease scheduled for PRRT was retrospectively analyzed. All patients underwent psycho-oncological screening before PRRT using HSI. Patients were stratified into four groups, based on their screening results and acceptance or refusal of psycho-oncological support. Clinical outcomes, including PFS and OS, were assessed, and subgroup analyses were performed to identify potential predictors of survival.Among 38 patients identified as needing psycho-oncological support, 9 accepted and 29 declined treatment. Patients who accepted psycho-oncological care demonstrated a 100% survival rate, comparable to patients with no significant distress. In contrast, patients who declined care exhibited a significantly shorter OS (median 83.7 months) and a higher death rate (38%). No differences were observed in PFS across groups. Subgroup analysis revealed similar tumor grading, pretreatment, and therapeutic regimens, suggesting that psychosocial factors influence OS independent of disease progression. Notably, women were more likely to accept psycho-oncological support than men.Psycho-oncological distress significantly impacts OS in NET patients undergoing PRRT. Acceptance of psycho-oncological care was associated with improved survival, highlighting the importance of integrating psychological support into routine NET management. These findings underscore the need for tailored psycho-oncological interventions, especially for patients at high risk who decline care. Further studies are warranted to elucidate the mechanisms linking psychosocial factors with clinical outcomes.</p>","PeriodicalId":94161,"journal":{"name":"Nuklearmedizin. Nuclear medicine","volume":" ","pages":"242-249"},"PeriodicalIF":1.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144532137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}